Treatment of acute pulmonary embolism after catheter-directed thrombolysis with dabigatran vs warfarin: Results of a multicenter randomized RE-SPIRE trial.
Alexander A GostevEmin ValievGalina A ZeidlitsEvgeniya A ShmidtOlesya S OsipovaAlexey V ChebanShoraan B SaayaOlga L BarbarashAndrey A KarpenkoPublished in: Journal of vascular surgery. Venous and lymphatic disorders (2024)
The results of the study show that dabigatran is comparable in effectiveness to warfarin. Dabigatran has greater safety in comparison with warfarin in the occurrence of all cases of bleeding in the postoperative and long-term periods. Thus, dabigatran may be recommended for the treatment and prevention of PE after CDT with RDT in patients with high and intermediate to high PE risk.
Keyphrases
- atrial fibrillation
- pulmonary embolism
- direct oral anticoagulants
- oral anticoagulants
- venous thromboembolism
- inferior vena cava
- phase iii
- randomized controlled trial
- double blind
- clinical trial
- risk assessment
- systematic review
- liver failure
- phase ii
- open label
- study protocol
- intensive care unit
- combination therapy
- cross sectional
- placebo controlled
- replacement therapy
- extracorporeal membrane oxygenation
- ultrasound guided
- clinical evaluation